The diagnosis and treatment of lung cancer have evolved into the era of precision medicine. inhibitor crizotinib. Soda fusion gene in non-small cell lung malignancy (NSCLC) in 2007. In 2008, results from a phase I study suggested that advanced ALK-positive NSCLCs might be sensitive to crizotinib.3 A phase I expansion cohort involving 149 patients with… Continue reading The diagnosis and treatment of lung cancer have evolved into the